Carbetocin
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Carbetocin: oxytocin receptor agonist → isotretinoin-like syndrome
One-Sentence Summary
Carbetocin is a long-acting oxytocin receptor agonist, used to prevent postpartum haemorrhage due to uterine atony. The TxGNN model predicts it may be relevant to isotretinoin-like syndrome, but there are currently 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | isotretinoin-like syndrome |
| TxGNN Prediction Score | 0.9915 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Carbetocin is known to act as an agonist at the oxytocin receptor (OXTR), and its clinical use is to prevent postpartum haemorrhage due to uterine atony. An intranasal formulation has also been under development for hyperphagia in Prader-Willi syndrome.
Isotretinoin-like syndrome is a congenital malformation condition resembling retinoic-acid embryopathy. No plausible rationale for oxytocin receptor agonism as a treatment for it can be drawn from the available data. The high model score (0.9915) is a computational output only, and it has not been corroborated by any trial or publication. The link should therefore be regarded as speculative.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02489244 | CARBETOCIN INJECTION | Not recorded | Not recorded |
| 02496526 | DURATOCIN | Not recorded | Not recorded |
Both licences are currently valid.
Safety Considerations
- Drug Interactions: The only record compiled is pharmacological: carbetocin acts on the oxytocin receptor (OXTR). No drug–drug interaction with a specific co-medication has been recorded.
Please refer to the package insert for further safety information, including warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting clinical trials or publications and no plausible mechanistic link, so the evidence level is L5 (model prediction only). It is not suitable for advancement at this stage.
To proceed, the following is needed:
- Mechanistic evidence connecting oxytocin receptor agonism to the pathology of isotretinoin-like syndrome
- Preclinical or clinical studies that directly address this disease
- Package insert warnings and contraindications from Health Canada for a safety review
- Confirmation of the routes of administration and dosage forms for the licensed products
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.